Granules India receives US FDA EIR with VAI classification for Bonthapally API facility Corporates · Oct 29, 2025
Granules India Q1 Results: Revenue jumps 2.56% YoY to Rs 1,210.11 crore, net profit falls 16.37% YoY Quarterly Results · Aug 12, 2025
Granules India’s Hyderabad unit receives one US FDA observation after Pre-Approval Inspection Corporates · Aug 1, 2025
Granules India clears US FDA Pre-Approval Inspection with zero observations Corporates · Jun 28, 2025
Granules India shares drop 3.6% after receiving US FDA warning letter for Gagillapur facility Stock Market · Feb 28, 2025
Granules India receives USFDA approval for Lisdexamfetamine Dimesylate Chewable tablets Corporates · Dec 17, 2024
Granules India says US FDA action may impact new product approvals, expect meet with FDA soon Corporates · Dec 4, 2024
Granules India stock falls over 10% from day’s high as US FDA classifies inspection as “Official Action Indicated” Stock Market · Dec 3, 2024
Granules India’s Gagillapur facility receives OAI classification from US FDA Corporates · Dec 3, 2024
Granules India shares surge 2% after US FDA grants ‘No Action Indicated’ status to Andhra Pradesh facility Stock Market · Nov 8, 2024
Granules India’s Andhra Pradesh facility receives ‘No Action Indicated’ status from US FDA Corporates · Nov 8, 2024
Granules India Q2 FY25 results: Stock jumps 2% ahead of result announcement Stock Market · Nov 6, 2024